2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Harnessing multimodal data integration to advance precision oncology

KM Boehm, P Khosravi, R Vanguri, J Gao… - Nature Reviews …, 2022 - nature.com
Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Targeted drug delivery strategies for precision medicines

MT Manzari, Y Shamay, H Kiguchi, N Rosen… - Nature Reviews …, 2021 - nature.com
Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Overcoming endocrine resistance in breast cancer

AB Hanker, DR Sudhan, CL Arteaga - Cancer cell, 2020 - cell.com
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Managing metastatic melanoma in 2022: a clinical review

B Switzer, I Puzanov, JJ Skitzki, L Hamad… - JCO oncology …, 2022 - ascopubs.org
Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

O Michielin, ACJ Van Akkooi, PA Ascierto… - Annals of …, 2019 - annalsofoncology.org
The European annual incidence of malignant melanoma varies from 3–5/100 000 in
Mediterranean countries to 12–35/100 000 in Nordic countries, whereas it can reach over …

The genomic landscape of endocrine-resistant advanced breast cancers

P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross… - Cancer cell, 2018 - cell.com
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …